{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Lantheus Holdings, Inc."},"Symbol":{"label":"Symbol","value":"LNTH"},"Address":{"label":"Address","value":"331 TREBLE COVE ROAD SOUTH BUILDING, NORTH BILLERICA, Massachusetts, 01862, United States"},"Phone":{"label":"Phone","value":"+1 978 671-8001"},"Industry":{"label":"Industry","value":"Biotechnology: In Vitro & In Vivo Diagnostic Substances"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.lantheus.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bela S. Denes","title":"Vice President-Global Medical Affairs"},{"name":"Brian A. Markison","title":"Chief Executive Officer & Director"},{"name":"Iryna Teslenko","title":"Vice President-Clinical Development"},{"name":"Jean-Claude Provost","title":"Chief Science Officer"},{"name":"Jeffrey S. Humphrey","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}